Deciphera Pharmaceuticals (DCPH) Stock Forecast for 2024–2028. Sell or Buy Prediction







Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Deciphera Pharmaceuticals (DCPH) Stock Forecast for 2024–2028. Sell or Buy?

Updated: April 23, 2024 (06:40)

Sector: Healthcare

The share price of Deciphera Pharmaceuticals, Inc. (DCPH) now

Latest session on the 23rd of April for
Deciphera Pharmaceuticals, Inc. is positive
Trading Volume: 426396
Open: 14.57 /  High: 15.2 /  Low: 14.56
What analysts predict: $24.2
52-week High/Low: $17.73 / $9.9

50/200 Day Moving Average: $15.65 / $14.05

This figure corresponds to the Average Price over the previous 50/200 days. For Deciphera Pharmaceuticals stocks, the 50-day moving average is the resistance level today.

For Deciphera Pharmaceuticals stocks, the 200-day moving average is the support level today.

Are you interested in Deciphera Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Deciphera Pharmaceuticals stock price in 2024, 2025, 2026, 2027, 2028. How much will one Deciphera Pharmaceuticals share be worth in 2024 - 2028?

When should I take profit in Deciphera Pharmaceuticals stock? When should I record a loss on Deciphera Pharmaceuticals stock? What are analysts' forecasts for Deciphera Pharmaceuticals stock? What is the future of Deciphera Pharmaceuticals stock? We forecast Deciphera Pharmaceuticals stock performance using neural networks based on historical data on Deciphera Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Deciphera Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Deciphera Pharmaceuticals shares. This happens once a day.


Historical and forecast chart of Deciphera Pharmaceuticals stock

The chart below shows the historical price of Deciphera Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Deciphera Pharmaceuticals stock price can be found in the table below.

Long-term forecasts by years.

Deciphera Pharmaceuticals, Inc. is a clinical research biopharmaceutical company.

The company develops drugs designed to improve the lives of cancer patients. Her drug candidates include DCC-2618, DCC-3014 and (Rebastinib) Rebastinib. The platform of kinase switching inhibitors developed by the Company suppresses the process of kinase activation. DCC-2618 is an orally administered inhibitor of kinase switching control for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas including glioblastoma multiforme (GBM), and other solid tumors caused by the pan-KIT or PDGFR gene alpha. DCC-3014 is an orally administered potent and highly selective colony stimulating factor receptor 1 (CSF1R) inhibitor. Rebastinib is a potent and selective oral immunokinase inhibitor of TIE2. Rebastinib binds tightly to the binding region (pocket) of the TIE2 switch, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Deciphera Pharmaceuticals daily forecast for a month

Date Target Pes. Opt. Vol., %
Apr 25 15.34 15.12 15.62 3.29
Apr 26 15.73 15.52 16.40 5.63
Apr 27 15.45 15.23 15.93 4.63
Apr 28 15.55 15.31 16.04 4.75
Apr 29 15.79 15.17 15.98 5.32
Apr 30 15.45 14.90 15.71 5.48
May 01 15.30 14.67 15.78 7.63
May 02 15.71 15.47 16.03 3.63
May 03 15.41 14.93 16.06 7.55
May 04 15.05 14.75 15.51 5.16
May 05 15.10 14.84 15.50 4.42
May 06 14.78 14.31 14.97 4.60
May 07 14.95 14.64 15.21 3.88
May 08 15.49 15.27 15.98 4.69
May 09 15.95 15.48 16.22 4.82
May 10 16.06 15.44 16.66 7.96
May 11 16.87 16.47 17.42 5.80
May 12 17.38 17.16 18.11 5.57
May 13 17.00 16.57 17.41 5.02
May 14 16.41 15.87 16.83 6.09
May 15 16.79 16.34 17.34 6.10
May 16 17.21 16.58 17.56 5.94
May 17 17.03 16.65 17.77 6.75
May 18 16.85 16.62 17.52 5.41
May 19 16.53 16.10 16.92 5.08
May 20 16.77 16.40 17.26 5.29
May 21 16.73 16.42 17.30 5.32
May 22 16.27 16.08 16.80 4.45
May 23 16.11 15.88 16.58 4.46
May 24 15.34 15.07 15.84 5.15

Deciphera Pharmaceuticals Daily Price Targets


Deciphera Pharmaceuticals Stock Forecast 04-25-2024.

Forecast target price for 04-25-2024: $15.34.
Positive dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 3.185%.
Pessimistic target level: 15.12
Optimistic target level: 15.62

Deciphera Pharmaceuticals Stock Forecast 04-26-2024.

Forecast target price for 04-26-2024: $15.73.
Positive dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 5.329%.
Pessimistic target level: 15.52
Optimistic target level: 16.40

Deciphera Pharmaceuticals Stock Forecast 04-27-2024.

Forecast target price for 04-27-2024: $15.45.
Negative dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 4.429%.
Pessimistic target level: 15.23
Optimistic target level: 15.93

Deciphera Pharmaceuticals Stock Forecast 04-28-2024.

Forecast target price for 04-28-2024: $15.55.
Positive dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 4.532%.
Pessimistic target level: 15.31
Optimistic target level: 16.04

Deciphera Pharmaceuticals Stock Forecast 04-29-2024.

Forecast target price for 04-29-2024: $15.79.
Positive dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 5.054%.
Pessimistic target level: 15.17
Optimistic target level: 15.98

Deciphera Pharmaceuticals Stock Forecast 04-30-2024.

Forecast target price for 04-30-2024: $15.45.
Negative dynamics for Deciphera Pharmaceuticals shares will prevail with possible volatility of 5.191%.
Pessimistic target level: 14.90
Optimistic target level: 15.71

DCPH (DCPH) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
May. 16.34 14.71 18.24 19.36
Jun. 17.19 14.58 18.19 19.85
Jul. 18.09 17.18 18.85 8.83
Aug. 14.58 13.18 16.18 18.56
Sep. 15.36 13.77 17.27 20.29
Oct. 15.86 14.40 18.39 21.72
Nov. 16.46 14.29 17.45 18.11
Dec. 17.45 15.91 19.82 19.72

Deciphera Pharmaceuticals forecast for this year


Deciphera Pharmaceuticals Stock Prediction for May 2024

An uptrend is forecast for this month with an optimal target price of $16.3424. Pessimistic: $14.71. Optimistic: $18.24


Deciphera Pharmaceuticals Stock Prediction for Jun 2024

An uptrend is forecast for this month with an optimal target price of $17.1922. Pessimistic: $14.58. Optimistic: $18.19


Deciphera Pharmaceuticals Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $18.0862. Pessimistic: $17.18. Optimistic: $18.85


Deciphera Pharmaceuticals Stock Prediction for Aug 2024

An downtrend is forecast for this month with an optimal target price of $14.5775. Pessimistic: $13.18. Optimistic: $16.18


Deciphera Pharmaceuticals Stock Prediction for Sep 2024

An uptrend is forecast for this month with an optimal target price of $15.3646. Pessimistic: $13.77. Optimistic: $17.27


Deciphera Pharmaceuticals Stock Prediction for Oct 2024

An uptrend is forecast for this month with an optimal target price of $15.8563. Pessimistic: $14.40. Optimistic: $18.39


Deciphera Pharmaceuticals Stock Prediction for Nov 2024

An uptrend is forecast for this month with an optimal target price of $16.4589. Pessimistic: $14.29. Optimistic: $17.45


Deciphera Pharmaceuticals Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $17.4464. Pessimistic: $15.91. Optimistic: $19.82



Deciphera Pharmaceuticals (DCPH) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 17.83 16.40 18.86 13.04
Feb 17.37 15.63 18.23 14.29
Mar 14.52 12.34 16.12 23.42
Apr 14.43 13.62 15.70 13.24
May 14.11 13.01 15.75 17.38
Jun 14.54 13.55 16.57 18.25
Jul 13.29 12.09 14.14 14.47
Aug 14.08 12.08 15.75 23.26
Sep 14.93 13.71 16.69 17.89
Oct 16.48 14.11 18.39 23.30
Nov 16.78 14.30 18.19 21.40
Dec 16.61 14.58 18.47 21.04

Deciphera Pharmaceuticals (DCPH) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 17.87 16.05 20.59 22.05
Feb 16.80 14.65 17.74 17.42
Mar 15.05 14.03 16.65 15.73
Apr 16.77 14.35 19.45 26.21
May 18.58 17.73 19.73 10.17
Jun 22.22 19.73 23.69 16.70
Jul 25.07 23.06 27.22 15.29
Aug 25.77 23.35 28.24 17.34
Sep 21.75 19.18 25.06 23.44
Oct 19.40 16.57 21.69 23.61
Nov 16.88 16.00 19.41 17.57
Dec 18.16 16.74 20.85 19.69

Deciphera Pharmaceuticals (DCPH) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 19.76 17.66 22.84 22.66
Feb 22.84 20.88 23.76 12.12
Mar 22.29 19.57 23.99 18.40
Apr 25.90 22.49 28.24 20.37
May 30.46 27.54 32.54 15.36
Jun 34.18 31.72 39.31 19.30
Jul 35.21 33.66 39.64 15.10
Aug 37.39 34.10 42.25 19.29
Sep 29.91 25.48 32.72 22.12
Oct 32.30 29.40 35.86 18.02
Nov 33.01 30.84 37.24 17.20
Dec 37.24 31.58 41.26 23.47

Deciphera Pharmaceuticals (DCPH) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 43.80 39.50 47.39 16.64
Feb 44.85 37.85 48.34 21.71
Mar 47.09 44.07 49.25 10.52
Apr 55.38 51.39 58.59 12.29
May 56.37 49.72 62.46 20.40
Jun 59.08 51.99 66.88 22.26
Jul 65.70 61.49 74.89 17.89
Aug 65.83 57.01 72.80 21.70
Sep 61.88 58.04 68.93 15.80
Oct 54.70 51.64 61.15 15.56
Nov 45.62 39.96 51.18 21.93
Dec 45.71 39.59 49.18 19.52

Deciphera Pharmaceuticals information and performance

Deciphera Pharmaceuticals Address

200 SMITH STREET, WALTHAM, MA, US

Market Capitalization: 1 185 337 000 $

Market capitalization of the Deciphera Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of DCPH shares in the company outstanding by the market price of one share.

EBITDA: -208 858 000 $

EBITDA of Deciphera Pharmaceuticals is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: None

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -2.29

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.329
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.32

Enterprise Value (EV) /Revenue

EV To EBITDA: -4.163

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 80800000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.